SARS-CoV-2 Sclamp Adjuvanted Vaccine
SARS-CoV-2 Sclamp Adjuvanted Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp Adjuvanted Vaccine. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established adjuvant technology, MF59, from Seqirus. The SARS-CoV-2 Sclamp Adjuvanted Vaccine Vaccine was developed within 3 weeks and moved immediately into preclinical testing through partnership with Dutch company, Viroclinics Xplore. Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response. As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). TetraQ, Australian National University (ANU), the University of Melbourne, and the Peter Doherty Institute for Infection and Immunity are also involved in the clinical component.
| Trade Name | SARS-CoV-2 Sclamp Adjuvanted Vaccine |
| Generic | SARS-CoV-2 Sclamp |
| SARS-CoV-2 Sclamp Other Names | SARS-CoV-2 Sclamp adjuvanted vaccine, UQ COVID-19 Vaccine, UQ-1-SARS-CoV-2-Sclamp |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here SARS-CoV-2 Sclamp Adjuvanted Vaccine
